OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Stress, mental disorder and ketamine as a novel, rapid acting treatment
Megan Dutton, Adem Can, Jim Lagopoulos, et al.
European Neuropsychopharmacology (2022) Vol. 65, pp. 15-29
Closed Access | Times Cited: 8
Megan Dutton, Adem Can, Jim Lagopoulos, et al.
European Neuropsychopharmacology (2022) Vol. 65, pp. 15-29
Closed Access | Times Cited: 8
Showing 8 citing articles:
Melanin-concentrating hormone: A promising target for antidepressant treatment
Limin Shi, Ying He, Yunsong Lian, et al.
Pharmacology Biochemistry and Behavior (2025) Vol. 250, pp. 173999-173999
Closed Access | Times Cited: 1
Limin Shi, Ying He, Yunsong Lian, et al.
Pharmacology Biochemistry and Behavior (2025) Vol. 250, pp. 173999-173999
Closed Access | Times Cited: 1
Escin ameliorates CUMS-induced depressive-like behavior via BDNF/TrkB/CREB and TLR4/MyD88/NF-κB signaling pathways in rats
Fengjiao Liu, Yunlong Jia, Liwei Zhao, et al.
European Journal of Pharmacology (2024) Vol. 984, pp. 177063-177063
Closed Access | Times Cited: 3
Fengjiao Liu, Yunlong Jia, Liwei Zhao, et al.
European Journal of Pharmacology (2024) Vol. 984, pp. 177063-177063
Closed Access | Times Cited: 3
Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression
Nelson B. Rodrigues, David Chen‐Li, Joshua D. Di Vincenzo, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 4, pp. 375-381
Open Access | Times Cited: 2
Nelson B. Rodrigues, David Chen‐Li, Joshua D. Di Vincenzo, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 4, pp. 375-381
Open Access | Times Cited: 2
Oral ketamine may offer a solution to the ketamine conundrum
Megan Dutton, Adem Can, Jim Lagopoulos, et al.
Psychopharmacology (2023) Vol. 240, Iss. 12, pp. 2483-2497
Open Access | Times Cited: 6
Megan Dutton, Adem Can, Jim Lagopoulos, et al.
Psychopharmacology (2023) Vol. 240, Iss. 12, pp. 2483-2497
Open Access | Times Cited: 6
Novel ketamine and zinc treatment for anorexia nervosa and the potential beneficial interactions with the gut microbiome
Rosiel Elwyn, Jules Mitchell, Michael Kohn, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 148, pp. 105122-105122
Closed Access | Times Cited: 5
Rosiel Elwyn, Jules Mitchell, Michael Kohn, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 148, pp. 105122-105122
Closed Access | Times Cited: 5
Protection of p-Coumaric acid against chronic stress-induced neurobehavioral deficits in mice via activating the PKA-CREB-BDNF pathway
Yanqun Cao, Hao Chen, Yinna Tan, et al.
Physiology & Behavior (2023) Vol. 273, pp. 114415-114415
Open Access | Times Cited: 3
Yanqun Cao, Hao Chen, Yinna Tan, et al.
Physiology & Behavior (2023) Vol. 273, pp. 114415-114415
Open Access | Times Cited: 3
Exploring genetic associations between vitiligo and mental disorders using Mendelian randomization
Ying-Wei Wang, Tao Yao, Yunlu Lin, et al.
Experimental Dermatology (2023) Vol. 33, Iss. 1
Closed Access | Times Cited: 2
Ying-Wei Wang, Tao Yao, Yunlu Lin, et al.
Experimental Dermatology (2023) Vol. 33, Iss. 1
Closed Access | Times Cited: 2
A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression
Adem Can, Daniel F. Hermens, Jim Lagopoulos
Clinical Case Reports (2022) Vol. 10, Iss. 12
Open Access | Times Cited: 4
Adem Can, Daniel F. Hermens, Jim Lagopoulos
Clinical Case Reports (2022) Vol. 10, Iss. 12
Open Access | Times Cited: 4
